Status:
RECRUITING
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Metastatic Colorectal Carcinoma
Metastatic Malignant Neoplasm in the Liver
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial evaluates the treatment response of colorectal cancer that has spread to the liver (liver metastases) using intravoxel incoherent motion diffusion weighted imaging (IVIM DWI). IVIM DWI is n...
Detailed Description
PRIMARY OBJECTIVE: I. To determine whether intravoxel incoherent motion (IVIM) diffusion weighted imaging (DWI) can detect a difference between the changes in the diffusion related parameters in pati...
Eligibility Criteria
Inclusion
- Patients with treatment-naive resectable CLM, who will start chemotherapy with oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with 5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent
- Patients with at least 1 colorectal liver metastasis measuring at least 1 cm
- Patients with anticipated follow-up before and after surgery at MD Anderson
Exclusion
- Patients who have already received preoperative chemotherapy for the CLM or will undergo radiation therapy, ablative therapies, or other non-surgical therapies directed at the liver
- Patients allergic to gadolinium
- Patients with pacemakers
- Greater than 400 pounds in weight
Key Trial Info
Start Date :
August 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04796818
Start Date
August 12 2020
End Date
January 31 2026
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030